A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL)

  • End date
    Dec 31, 2022
  • participants needed
  • sponsor
    Beijing InnoCare Pharma Tech Co., Ltd.
Updated on 28 February 2022


The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.

Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with R/R MZL will be evaluated in approximately 80 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects.

Condition MZL
Treatment ICP-022
Clinical Study IdentifierNCT03797456
SponsorBeijing InnoCare Pharma Tech Co., Ltd.
Last Modified on28 February 2022


Yes No Not Sure

Inclusion Criteria

Men and women between 18 and 75 years old
Histologically confirmed marginal zone lymphoma (MZL), and at least one measurable tumor of greater than 1.5 centimeter outside of the spleen
Subjects with refractory or relapsed MZL who has received at least 1 but no more than 4 prior therapies for MZL
ECOG performance status of 0-2
Documented failure to achieve at least partial response (PR) or documented disease progression after response to the most recent treatment regimen
Subjects who have indications for treatment (threatened end-organ function, bulky disease >5cm, symptoms, steady progression, wish to treat)
Subjects meet the following laboratory parameters
Absolute neutrophil count (ANC) 1.5109/L Platelet count 75109/L, independent of growth factor support within 7 days of the first dose with study drug, Hemoglobin 75 g/L; ANC 1.0109/L, Platelet count 50109/L, Hemoglobin 50 g/L; if bone marrow involvement
Total bilirubin 1.5 ULN; AST or ALT 2 ULN; Creatinine 1.5 ULN; Amylase ULN and Lipase ULN
International normalized ratio (INR) 1.5 ULN
Life expectancy 3 months
Able to provide signed written informed consent

Exclusion Criteria

History of other active malignancies within 5 years of study entry, unless cured without evidence of relapse or metastasis
Current or history of lymphoma involved central nervous system
Prior corticosteroids (at dosages equivalent to prednisone > 20 mg/day) given with anti-neoplastic intent within 7 days, prior chemotherapy, targeted therapy, radiation therapy, or antibody-based therapies or anti-cancer TCM within 4 weeks of the start of study drug
Non-hematological toxicity must recover to Grade 1 from prior anti-cancer therapy (except for alopecia)
Current clinically significant cardiovascular disease including
Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) < 50%
Primary cardiomyopathy
Clinical significant QTc prolong history or QTc>470ms (female) QTc>450ms (male)
Uncontrolled hypertension
Known active bleeding within 2 months of screening or currently taking anticoagulant/antiplatelet drugs
Urine protein 2+ and quantitation 2g/24hours
History of deep vein thrombosis or pulmonary embolism
Toxicity must be recovered to Grade 1 from prior anti-cancer therapy
Disease significantly affecting gastrointestinal function such as dysphagia, chronic diarrhea, intestinal obstruction, or resection of the stomach
Prior organ or hematopoietic stem cell transplant
Major surgery within 6 weeks of screening, except for diagnostic test or vascular access setup
Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection
Any history of pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe lung function impairment
Prior exposure to a BTK or BCR pathway inhibitor (PI3K or Syk) and BCL-2 inhibitor
Suitable and ready for allogeneic stem cell transplant
Inability to comply with study procedures
Drug abuser or alcoholics
Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children
Requires treatment with moderate or strong cytochrome P450 family 3, subfamily A (CYP3A) inhibitors or strong CYP3A inducers
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note